Takeda Pharmaceutical Company Limited (TAK): Price and Financial Metrics
GET POWR RATINGS... FREE!
TAK POWR Grades
- TAK scores best on the Value dimension, with a Value rank ahead of 98.84% of US stocks.
- The strongest trend for TAK is in Momentum, which has been heading down over the past 48 weeks.
- TAK ranks lowest in Momentum; there it ranks in the 13th percentile.
TAK Stock Summary
- Price to trailing twelve month operating cash flow for TAK is currently 0.05, higher than merely 1.12% of US stocks with positive operating cash flow.
- The volatility of Takeda Pharmaceutical Co Ltd's share price is greater than that of merely 2.69% US stocks with at least 200 days of trading history.
- Takeda Pharmaceutical Co Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 1,596.53%, greater than the shareholder yield of 99.65% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Takeda Pharmaceutical Co Ltd, a group of peers worth examining would be TEL, BSX, IFF, PHG, and CTVA.
- Visit TAK's SEC page to see the company's official filings. To visit the company's web site, go to www.takeda.com.
TAK Stock Price Chart Interactive Chart >
TAK Price/Volume Stats
|Current price||$17.00||52-week high||$19.97|
|Prev. close||$17.22||52-week low||$15.30|
|Day high||$17.19||Avg. volume||2,694,491|
|50-day MA||$16.81||Dividend yield||3.95%|
|200-day MA||$17.39||Market Cap||53.80B|
Takeda Pharmaceutical Company Limited (TAK) Company Bio
Takeda Pharmaceutical Company Limited is engaged in research and development, manufacturing, sales and marketing, and import and export of pharmaceutical drugs. The Company focuses on the core therapeutic areas of oncology, gastrointestinal, and central nervous system disease.
Most Popular Stories View All
TAK Latest News Stream
|Loading, please wait...|
TAK Latest Social Stream
View Full TAK Social Stream
Latest TAK News From Around the Web
Below are the latest news stories about Takeda Pharmaceutical Co Ltd that investors may wish to consider to help them evaluate TAK as an investment opportunity.
(RTTNews) - Mirum Pharmaceuticals, Inc. (MIRM) and Takeda Pharmaceutical Company Limited (TAK) have entered into an exclusive licensing agreement for the development and commercialization of maralixibat in Japan for Alagille syndrome, progressive familial intrahepatic cholestasis, and biliary atresia. Under the agreement, Takeda will be
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for maralixibat in Japan for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA). Under the terms of the agreement, Takeda will be responsible for regulatory approval and commercialization of maralixibat in Japan. Takeda will also be responsible for the development, including conducting clinical stud
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
FOSTER CITY, Calif. & OSAKA, Japan, September 21, 2021--Mirum and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
Global Rubella Treatment Market Valuable Growth Prospects, Top Players, Key Country Analysis, Trends and Forecast till 2028||Dr. Reddys Laboratories Ltd, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Takeda Pharmaceutical Co
Advanced report on Rubella Treatment Market Added by Data Bridge Market Research, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the Rubella Treatment
Takeda Pharmaceutical said on Wednesday the US Food and Drug Administration approved its drug, Exkivity, to treat a type of lung cancer. Takeda said the approval was based on an early-to-mid-stage trial testing 114 patients with non-small cell lung cancer, with results showing clinically meaningful responses with a median duration of about 18 months. Exkivity  The post Exkivity: US approves drug for lung cancer appeared first on ARY NEWS .
TAK Price Returns
|Ex-Dividend Date||Type||Payout Amount||Change|
|Loading, please wait...|